The Phase 3-stage biopharmaceutical company is focused on discovering and developing small molecule drug candidates to treat cancer, with a focus on myelodysplastic syndromes (MDS).
Onconova Therapeutics anticipates positive pivotal trial readout by the first half of 2020
Quick facts: Onconova Therapeutics
Price: 0.5776 USD
Market Cap: $100.6 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE